Suppr超能文献

阿尔茨海默病中的组蛋白修饰。

Histone Modifications in Alzheimer's Disease.

机构信息

Department of Morphology & Genetics, Universidade Federal de São Paulo (UNIFESP), São Paulo 04023-062, SP, Brazil.

出版信息

Genes (Basel). 2023 Jan 29;14(2):347. doi: 10.3390/genes14020347.

Abstract

Since Late-onset Alzheimer's disease (LOAD) derives from a combination of genetic variants and environmental factors, epigenetic modifications have been predicted to play a role in the etiopathology of LOAD. Along with DNA methylation, histone modifications have been proposed as the main epigenetic modifications that contribute to the pathologic mechanisms of LOAD; however, little is known about how these mechanisms contribute to the disease's onset or progression. In this review, we highlighted the main histone modifications and their functional role, including histone acetylation, histone methylation, and histone phosphorylation, as well as changes in such histone modifications that occur in the aging process and mainly in Alzheimer's disease (AD). Furthermore, we pointed out the main epigenetic drugs tested for AD treatment, such as those based on histone deacetylase (HDAC) inhibitors. Finally, we remarked on the perspectives around the use of such epigenetics drugs for treating AD.

摘要

由于晚发性阿尔茨海默病(LOAD)源于遗传变异和环境因素的综合作用,因此预测表观遗传修饰在 LOAD 的发病机制中发挥作用。除了 DNA 甲基化,组蛋白修饰也被认为是导致 LOAD 病理机制的主要表观遗传修饰;然而,对于这些机制如何导致疾病的发生或进展知之甚少。在这篇综述中,我们强调了主要的组蛋白修饰及其功能作用,包括组蛋白乙酰化、组蛋白甲基化和组蛋白磷酸化,以及在衰老过程中主要在阿尔茨海默病(AD)中发生的这些组蛋白修饰的变化。此外,我们还指出了针对 AD 治疗测试的主要表观遗传药物,如基于组蛋白去乙酰化酶(HDAC)抑制剂的药物。最后,我们提到了使用这些表观遗传学药物治疗 AD 的前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86ed/9956192/3d87a75ac0d0/genes-14-00347-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验